Pharmaceutical Executive Issue Alert Having trouble viewing this email? Click here
Web Version | Share with a colleague | View Digital Edition | Subscribe
In our March issue of Pharmaceutical Executive
FEATURES
Cover Story
 Vaccines 2016: Big Bets for Global Threats
Casey McDonald
A new wave of technologies supported by innovative business models is transforming the vaccine landscape — and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.
Strategy
Beyond 2020: Building Strategic Coherence in the New Health Economy
Rick Edmunds, Jo Pisani, Douglas Strang, Michael Swanick
Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Roundtable
 Drug Delivery: More Than the Pill
 William Looney
New testing and delivery platforms — from 3D printing of molecules to ingestible miniaturized “nanobots” — promise more precise therapeutic outcomes as well as the standard benefits from increased utilization and higher rates of adherence. Pharm Exec convened a roundtable with top executives from four start-up companies committed to scoring big in this emerging field.
R&D
 What Errors Do We Miss in Clinical Trials
 Clara Heering
This article examines the deficits in current risk mitigation approaches and presents a new paradigm for risk management that is aligned with the new ICH GCPguidelines.
ALSO IN THIS ISSUE
 Can FDA Control Drug Prices
Jill Wechsler
More generics and biosimilars may generate competition — but FDA opposes broad compounding.

 Orphans of the Storm
Reflector
Europe’s contrasting views on rare disease drugs — one bashing pricing abuses, the other extolling their public health virtues — could ultimately leave these products out in the cold.

Data Disclosure: Sealing the Error Envelope
William Looney
With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind — and serve as a reminder to companies that true transparency depends on the truthfulness of the evidence that binds it.
 
WEBCASTS
Four Strategies You Need to Maximize the Value of Your Data
New Tufts CSDD Research: Industry Adoption of eClinical Solutions and CDISC Standards
The Growing Aging Consumer Population – Living Longer, Living Smarter
Engineer Your Business to Win in the Mobile Selling Moment
 
Download the
issue:
 
image

Pharmaceutical Executive is free to qualified subscribers. To subscribe, click here.

Click here to contact the Pharmaceutical Executive sales team.
Twitter LinkedIn